Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Kidney drug trial pulled before it even started

NCT ID NCT06120673

First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 20 times

Summary

This was a planned Phase 3 trial to test the drug obinutuzumab against a standard treatment (steroids and cyclophosphamide) for people with primary membranous nephropathy, a kidney disease. The goal was to see which treatment worked better at reducing protein in the urine, with fewer side effects and better quality of life. However, the trial was withdrawn before enrolling any participants, so no results are available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Bundaberg Hospital

    Bundaberg, Queensland, Australia

  • Cairns Hospital

    Cairns, Queensland, Australia

  • Canberra Hospital

    Garran, Australian Capital Territory, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Logan Hospital

    Logan City, Queensland, Australia

  • Mackay Base Hospital

    Mackay, Queensland, Australia

  • Mater Hospital

    South Brisbane, Queensland, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Rockhampton Hospital

    Rockhampton, Queensland, Australia

  • Royal Brisbane and Women's Hospital

    Brisbane, Queensland, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Obinutuzumab

Conditions

The condition(s) this trial relates to.

membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.